New member: Adjutec Pharma
In this article series, we will introduce the new members of our oncology cluster.
Antibiotic resistance is one of the treats for cancer patients’ survival. Meet our new member Adjutec Pharma, a company with new technology against multi-drug resistant bacteria.
Multi-drug resistant bacteria are spreading across the globe and cannot easily be treated with antibiotics. Cancer patients are an especially vulnerable group, because their immune systems may be extra susceptible to different bacteria and virus while undergoing treatment.
In Norway, new technology has been developed to combat multi-drug resistant bacteria. We asked the founder of the company Adjutec Pharma, Professor Pål Rongved, to tell us more about this new tecknologi.
Who is Adjutec Pharma and how are you involved in health and cancer?
Antibiotic resistance can render modern medicine useless, if new technology is not found. The biotech start-up AdjuTec Pharma AS was established in 2019 by the main grounder, Professor Pål Rongved, UiO, to develop their cutting edge technology (ZinChel). Their compounds have proved very effective as low-toxic adjuvants in combination with last resort antibiotics against a wide range of multidrug-resistant Gram-negative bacteria. These are increasingly spreading across the globe. These bacteria are at the top of the WHO’s list of 12 ‘priority pathogens’, representing the most dangerous bacteria in the world.
Why did Adjutec Pharma become a member of Oslo Cancer Cluster?
“About 20 % of the cancer patients are dying from infectious diseases, making the technology highly relevant for the cancer clinic. The OCC Incubator is a unique partner for networking and a number of services that aids exchange of expertise, comprises a spectrum of companies, institutions and organizations. This gives a valuable opportunity to contribute to aiding the cancer patients with their secondary infections, and further stimulates research collaborations,” said Rongved.
- Read more about Adjutec Pharma in this article on Aftenposten Viten (in Norwegian) and in this article at Science Norway’s website (in English)